TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33155711
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n=232)
Study: 35550672
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture containing four strains of Bifidobacterium species and one Lacticaseibacillus strain, administered daily, dosage not specified, duration not specified.
Study: 35533640
Drug: Salinity-resistant ecotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salinity-resistant ecotypes (e.g., 'AE5')
Study: 35533640
Drug: Salinity-susceptible ecotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salinity-susceptible ecotypes (e.g., 'AE3')
Study: 35772250
Drug: EEG-guided anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG-guided anesthesia (EEG-G)
Study: 35772250
Drug: EEG-guided anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG-guided anesthesia (EEG-G) and Standard care (SC)
Study: 34269090
Drug: Hematology/oncology drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematology/oncology drugs with pediatric label changes
Study: 34269090
Drug: Hematology/oncology drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematology/oncology drugs with pediatric indications
Study: 34269090
Drug: Hematology/oncology drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematology/oncology drugs that failed to receive pediatric indications
Study: 32473356
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 or 600 mg loading dose)
Study: 32473356
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily for 30 days
Study: 32473356
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily for 30 days
Study: 33581295
Drug: Multisite injection
Normalized name: polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisite injection therapy (2 mL of triamcinolone acetonide, 4 mL of bupivacaine, and 34 mL of saline solution)
Study: 33581295
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection therapy (1 mL of triamcinolone acetonide and 2 mL of bupivacaine)
Study: 33581295
Drug: Multisite injection
Normalized name: polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisite injection therapy
Study: 33581295
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection therapy
Study: 35413116
Drug: Idasanutlin 300
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin 300 mg plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles
Study: 35413116
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles
Study: 34535176
Drug: Cisplatin intravenous
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin intravenous drip (Group A)
Study: 32692493
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) administration as a bolus followed by continuous infusion
Study: 32692493
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) administration
Study: 33839788
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise (COMB)
Study: 33900803
Drug: Oral Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chemotherapy Management Program (OCMP)
Study: 34791107
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks)
Study: 33647588
Drug: Biological sex
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological sex differences
Study: 36205248
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg daily for 45 days after hospital discharge
Study: 34546614
Drug: L-PRP application
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRP application onto the sutured fascia
Study: 34546614
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no L-PRP application)
Study: 32242760
Drug: Interactive tablet
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive tablet 'app' consent process
Study: 35973906
Drug: Budesonide Oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Oral Suspension
Study: 32379992
Drug: Probiotic tablets
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic tablets containing Weissella cibaria CMU (1 × 10^8 CFU/g)
Study: 36476623
Drug: Single-dose dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose dalbavancin
Study: 36476623
Drug: Two-dose dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose dalbavancin
Study: 36476623
Drug: Comparator antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator antibiotic
Study: 37295011
Drug: Melodic Intonation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melodic Intonation Therapy (MIT)
Study: 33808784
Drug: Bioavailable diosmin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavailable diosmin (μsmin® Plus) 450 mg tablet once daily for 8 weeks
Study: 32867992
Drug: CWE (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CWE (basal diet + 1,000 mg/kg chestnut tannins)
Study: 35227777
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg every week (ew) maintenance regimen
Study: 35227777
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg every other week (eow) maintenance regimen
Study: 35227777
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ew maintenance regimen (integrated population)
Study: 35227777
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg eow maintenance regimen (integrated population)
Study: 34227397
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker
Study: 32939546
Drug: Ad26,ZEBOV (Ad26)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26,ZEBOV (Ad26) and MVA-BN-Filo (MVA) vaccines
Study: 32939546
Drug: Heterologous two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous two-dose Ad26,MVA regimens
Study: 34843406
Drug: Ro-CHOP (Romidepsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro-CHOP (Romidepsin 12 mg/m² IV on days 1 and 8 of each 3-week cycle for six cycles)
Study: 34098994
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture treatment (20 sessions, 5 sessions per week)
Study: 34098994
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment (20 sessions, 5 sessions per week)
Study: 34749994
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone 1 mg kg‐1
Study: 34749994
Drug: Intermediate-dose dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose dexamethasone 0.3 mg kg‐1
Study: 34824001
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and lumbar segmental stabilization
Study: 34824001
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and lumbar segmental stabilization plus specific hip strengthening
Study: 35015038
Drug: 6-week anticoagulant
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week anticoagulant therapy (n=207)
Study: 35015038
Drug: 3-month anticoagulant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month anticoagulant therapy (n=210)
Study: 32590944
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 ml saline)
Study: 33731163
Drug: Modern medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern medicine (pirfenidone) plus TCM
Study: 33731163
Drug: Modern medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern medicine plus TCM placebo
Study: 35405009
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors
Study: 616973594
Drug: Combined cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined cabergoline (0.5 g weekly) and metformin (1000 mg daily) for 3 months
Study: 616973594
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg daily) and placebo for 3 months
Study: 33602710
Drug: Hypochlorous acid
Normalized name: Hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypochlorous acid (HOCl) wound solution
Study: 33602710
Drug: Placebo wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo wound solution
Study: 33864830
Drug: ALA+SFC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA+SFC (100 and 115 mg/day)
Study: 32762882
Drug: Peg‐ IFNα
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐ IFNα (180 mcg/week) with TDF (300 mg/day)
Study: 32762882
Drug: TDF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF (300 mg/day)
Study: 32762882
Drug: Peg‐ IFNα
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐ IFNα (180 mcg/week)
Study: 32762882
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Peg‐ IFNα and TDF)
Study: 32762882
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with Peg‐IFNα
Study: 32762882
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with TDF
Study: 33896436
Drug: Online Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Family Problem-Solving Therapy (OFPST)
Study: 35837991
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg daily
Study: 33109244
Drug: Boron compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron compounds (5 mg) twice a day for two weeks
Study: 33109244
Drug: Oleoylethanolamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleoylethanolamide (200 mg) twice a day for two weeks
Study: 33109244
Drug: Boron compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron compounds (5 mg) with oleoylethanolamide (200 mg) twice a day for two weeks
Study: 33109244
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments only (no additional treatment)
Study: 32367694
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen at 4 L/min via nasal cannula during exercise
Study: 32367694
Drug: Placebo air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo air at 4 L/min via nasal cannula during exercise
Study: 33992717
Drug: Once-daily CCTRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily CCTRT at 65 Gy in 26 fractions
Study: 33992717
Drug: Twice-daily CCTRT
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily CCTRT at 45 Gy in 30 fractions
Study: 32638615
Drug: Personalized Integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized Integrative Therapy (PI Therapy)
Study: 32638615
Drug: Personalized Integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized Integrative Therapy + Nutritional Supplements (PI Therapy + Supps)
Study: 35947349
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks (Q8W)
Study: 32723804
Drug: Daprodustat 4
Normalized name: daprodustat 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 4 mg once daily
Study: 32723804
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 10-60 μg once weekly
Study: 34787656
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 5 mg or 10 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Study: 34787656
Drug: Combination acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination acetaminophen and codeine 500 mg and 8 mg or 1000 mg and 16 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Study: 32712663
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (PET)
Study: 32682357
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Study: 32682357
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Study: 32682357
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Study: 38081955
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral pre-exposure prophylaxis (PrEP) for HIV prevention
Study: 36424662
Drug: Accelerated renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated renal replacement therapy (RRT) initiation
Study: 36424662
Drug: Standard renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard renal replacement therapy (RRT) initiation
Study: 34535644
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg twice a day of berberine ursodeoxycholate
Study: 34822189
Drug: Intravenous L-ornithine
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-ornithine L-aspartate (LOLA) at a dose of 30 g over 24 hours for 5 days, combined with lactulose and rifaximin
Study: 34822189
Drug: Intravenous L-ornithine
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-ornithine L-aspartate (LOLA)
Study: 32416690
Drug: HGF gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF gene therapy (naked plasmid DNA encoding hepatocyte growth factor)
Study: 35256225
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia (300 mg gabapentin, 200 mg celecoxib, 500 mg acetaminophen 2 hours before surgery)
Study: 37222189
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with mFOLFIRINOX
Study: 32469893
Drug: Intramuscular electroporation
Normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular electroporation of HIV-MAG DNA vaccine
Study: 33477316
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy + exercise
Study: 36202198
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir 300 mg
Study: 36202198
Drug: Oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oseltamivir 75 mg
Study: 35277038
Drug: Enzyme-modified oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-modified oil oral nutritional supplement (EMO-ONS)
Study: 32574844
Drug: SCF (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF (12 g/d)
Study: 32574844
Drug: SCF (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF (12 g/d) + 600 mg/d of calcium
Study: 32574844
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 600 mg/d of calcium
Study: 36224575
Drug: Robotic-assisted balance
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted balance treatment using the Hunova® robotic platform for 3 times a week, for 4 weeks (12 total sessions), 45 min of treatment, in addition to conventional treatment.
Study: 36224575
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment as per daily routine.
Study: 34836225
Drug: 770 mg
Normalized name: aspirin 770 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 770 mg of Tribulus terrestris L. supplementation
Study: 32687266
Drug: Eflapegrastim (13.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflapegrastim (13.2 mg, 3.6 mg G-CSF)
Study: 36147622
Drug: Enhanced lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced lower limb therapy (ELLT)
Study: 36147622
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy (CRT)
Study: 35368494
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (daily text message for 30 days)
Study: 32636425
Drug: Domestic nano‐hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic nano‐hydroxyapatite remineralizing gel
Study: 32636425
Drug: In-office ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office ozone therapy
Study: 32636425
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of domestic remineralizing gel and ozone therapy
Study: 34344607
Drug: People-centred care
Approvals — FDA: no, EMA: no, PMDA: no
Description: People-centred care model (PCCM) including pharmacist-led clinical medication review
Study: 34092112
Drug: Platinum agents
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum agents
Study: 36415651
Drug: Paramedic-administered breathlessness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paramedic-administered breathlessness management intervention plus usual care
Study: 32786188
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy plus education on cellulitis prevention
Study: 34475328
Drug: Aggressive lipid-modifying
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid-modifying therapy combined with inflammatory modulation.
Study: 32951729
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of baru almond oil (BG)
Study: 32951729
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of mineral oil (placebo, BP)
Study: 35837991
Drug: glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 2 mg
Study: 35872749
Drug: Heat-killed Lactiplantibacillus
Normalized name: Lactiplantibacillus plantarum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactiplantibacillus plantarum L-137 (HK L-137)
Study: 32961806
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 1: 120 kVp, 25 mAs
Study: 32961806
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 2: 100 kVp, 15 mAs
Study: 32961806
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 3: 120 kVp, 5 mAs
Study: 32961806
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 4: 100 kVp, 5 mAs
Study: 34017122
Drug: Antitumor induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitumor induction therapy
Study: 38848522
Drug: Oral cetirizine
Normalized name: cetirizine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cetirizine
Study: 35978334
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components (motivational counseling, nicotine replacement patches/lozenges, message framing)
Study: 35978334
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components
Study: 34906386
Drug: Autologous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fat grafting (AFG) protocol with a single injection of autologous fat grafting and dressed with nano fat (Group A)
Study: 34906386
Drug: Conventional methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methods of serial dressings with 1% silver sulphadiazine or other topical agents (Group B)
Study: 34529000
Drug: Neoadjuvant paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant paclitaxel plus investigational agents (graduated treatments)
Study: 34529000
Drug: Neoadjuvant paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant paclitaxel plus investigational agents (non-graduated treatments)
Study: 34529000
Drug: Neoadjuvant paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant paclitaxel plus chemotherapy alone (control)